AB Science SA

Communication from AB Science following the decision of the Enforcement Committee of the French market regulator (AMF)

29 3 2022 12:57:17 提供 Nasdaq GlobeNewswire

AB Science announces the financing of a 8.5 million dollars through the issuance of convertible bonds with attached warrants

28 2 2022 01:00:53 提供 Nasdaq GlobeNewswire

AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indications

24 2 2022 11:08:12 提供 Nasdaq GlobeNewswire

AB Science announces the publication of the masitinib positive pivotal Phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation

22 2 2022 11:08:18 提供 Nasdaq GlobeNewswire

AB Science announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of ALS under the Notice of Compliance with Conditions (NOC/c) policy

21 2 2022 10:48:11 提供 Nasdaq GlobeNewswire

AB Science - Clarification following the February 11, 2022 public hearing of the Enforcement Committee of the French Market Regulator (AMF)

12 2 2022 13:49:07 提供 Nasdaq GlobeNewswire

AB Science to present on its Amyotrophic Lateral Sclerosis (ALS) development program at the 2022 ALS Drug Development Summit

07 2 2022 11:12:11 提供 Nasdaq GlobeNewswire

AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency

02 2 2022 11:13:01 提供 Nasdaq GlobeNewswire

AB Science has been granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health Authority (ANSM)

19 1 2022 11:02:50 提供 Nasdaq GlobeNewswire

AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)

03 1 2022 11:10:59 提供 Nasdaq GlobeNewswire

AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus

29 11 2021 13:57:09 提供 Nasdaq GlobeNewswire

AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia

22 11 2021 11:20:45 提供 Nasdaq GlobeNewswire

AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS

18 11 2021 13:40:53 提供 Nasdaq GlobeNewswire

AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)

18 10 2021 11:14:05 提供 Nasdaq GlobeNewswire

AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)

04 10 2021 11:10:54 提供 Nasdaq GlobeNewswire

AB Science today reports its revenues for the first half of 2021 and provides an update on its activities

30 9 2021 12:21:10 提供 Nasdaq GlobeNewswire

AB Science receives regulatory authorization to commence a second Phase 2 Covid-19 study

28 9 2021 12:25:22 提供 Nasdaq GlobeNewswire

AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)

22 9 2021 11:09:23 提供 Nasdaq GlobeNewswire

AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology

20 9 2021 12:15:45 提供 Nasdaq GlobeNewswire

AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)

16 9 2021 12:34:08 提供 Nasdaq GlobeNewswire